Phenyl-Substituted Imidazole Compounds Targeting Androgen Receptor Nuclear Localization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for castration-resistant prostate cancer (CRPC) do not effectively block the nuclear localization of the androgen receptor (AR), which is crucial for the progression and growth of prostate tumors, as existing treatments like Abiraterone and MDV3100 either inhibit testosterone synthesis or impair AR nuclear translocation but not comprehensively.
Innovation Solution
Administration of specific phenyl-substituted imidazole compounds or their pharmaceutically acceptable salts, which inhibit AR nuclear localization in CRPC cells, reducing the nuclear level of AR and thereby inhibiting its activation, as exemplified by compounds like SID 14730725 and SID 3712502, which target AR without affecting other transcription factors like GR and ER.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments like Abiraterone and MDV3100 are used, then testosterone synthesis is inhibited or AR nuclear translocation is impaired, but AR nuclear localization is not effectively blocked
Solution Approach 1:
The patent employs small molecule compounds that induce conformational changes in the androgen receptor structure, altering its nuclear localization properties. This parameter change approach transforms the AR from a nuclear-localized state to a cytoplasmic-retained state, effectively blocking its oncogenic activity without requiring complete receptor inhibition
Solution Approach 2:
The invention introduces small molecule compounds as intermediary agents that mediate between the androgen receptor and its nuclear localization process. These compounds act as molecular mediators that interfere with the AR-nuclear import machinery interaction, preventing AR from reaching its functional destination in the nucleus while maintaining physiological androgen signaling pathways
2Reliability
If AR nuclear translocation is impaired, then AR activation is reduced, but existing therapies do not comprehensively block nuclear localization
Solution Approach 1:
The patent extracts and targets the specific nuclear localization function of the androgen receptor separately from its other functions. By developing compounds that specifically interfere with AR nuclear import while leaving other AR activities intact, the invention isolates and addresses the pathological nuclear localization aspect of CRPC, providing a more targeted and comprehensive therapeutic approach
Solution Approach 2:
Instead of trying to enhance AR nuclear translocation as in normal physiology, the patent inverts the approach by developing compounds that actively block and reverse AR nuclear localization in CRPC cells. This inversion strategy transforms the natural physiological process into its opposite, preventing the aberrant nuclear accumulation of AR that drives castration-resistant prostate cancer
3Productivity
If small molecules targeting AR nuclear localization are used, then tumor growth and PSA expression are decreased, but specificity to AR-positive cells must be maintained
Solution Approach 1:
The patent applies the local quality principle by designing small molecule compounds with specific molecular features that confer selectivity for AR-positive cells. The compounds possess particular structural characteristics and binding properties that enable them to interact specifically with the androgen receptor in prostate cancer cells while leaving other cell types unaffected, thereby achieving localized therapeutic action with minimal off-target effects
Data Source
AI summary
A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from:(a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or(b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group;R21 is an alkanediyl or a substituted alkanediyl;a is 0 or 1;c is 0 or 1;X is C or S;R22 is a moiety that includes at least one divalent amino radical; andR23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group.